ES533668A0
(es)
*
|
1983-06-24 |
1985-10-01 |
Yamanouchi Pharma Co Ltd |
Un compuesto fenoxi
|
CN1003445B
(zh)
*
|
1984-10-03 |
1989-03-01 |
武田药品工业株式会社 |
噻唑烷二酮衍生物,其制备方法和用途
|
US4812570A
(en)
*
|
1986-07-24 |
1989-03-14 |
Takeda Chemical Industries, Ltd. |
Method for producing thiazolidinedione derivatives
|
FI91869C
(fi)
*
|
1987-03-18 |
1994-08-25 |
Tanabe Seiyaku Co |
Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
|
HU203330B
(en)
*
|
1987-06-10 |
1991-07-29 |
Pfizer |
Process for producing oxazolidin-2-one derivatives and hypoglychemic pharmaceutical compositions containing them
|
EP0295828A1
(en)
*
|
1987-06-13 |
1988-12-21 |
Beecham Group Plc |
Novel compounds
|
GB8713861D0
(en)
*
|
1987-06-13 |
1987-07-15 |
Beecham Group Plc |
Compounds
|
US4798835A
(en)
*
|
1987-12-02 |
1989-01-17 |
Pfizer Inc. |
dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent
|
US4791125A
(en)
*
|
1987-12-02 |
1988-12-13 |
Pfizer Inc. |
Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
|
GB8820389D0
(en)
*
|
1988-08-26 |
1988-09-28 |
Beecham Group Plc |
Novel compounds
|
GB8919417D0
(en)
|
1989-08-25 |
1989-10-11 |
Beecham Group Plc |
Novel compounds
|
US4997948A
(en)
*
|
1989-10-27 |
1991-03-05 |
American Home Products |
5-[(1- and 2-naphthalenyl) sulfonyl]-2,4-thiazolidinediones and derivatives thereof
|
US5356913A
(en)
*
|
1990-02-09 |
1994-10-18 |
The Upjohn Company |
Use of insulin sensitizing agents to treat hypertension
|
ATE93138T1
(de)
*
|
1990-02-09 |
1993-09-15 |
Upjohn Co |
Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
|
DE69132713D1
(de)
*
|
1990-04-27 |
2001-10-11 |
Sankyo Co |
Benzylidenthiazolidinderivate, ihre Herstellung und ihre Anwendung als Lipidperoxid-Inhibitoren
|
GB9023584D0
(en)
*
|
1990-10-30 |
1990-12-12 |
Beecham Group Plc |
Novel compounds
|
US5158966A
(en)
*
|
1991-02-22 |
1992-10-27 |
The University Of Colorado Foundation, Inc. |
Method of treating type i diabetes
|
US5441971A
(en)
*
|
1991-04-11 |
1995-08-15 |
The Upjohn Company |
Thiazolidinedione derivatives, production and use thereof
|
HUT68370A
(en)
*
|
1991-04-11 |
1995-06-28 |
Takeda Chemical Industries Ltd |
Thiazolidine derivatives, pharmaceutical compositions containing them and process for their production
|
US5183823A
(en)
*
|
1991-04-11 |
1993-02-02 |
Takeda Chemical Industries, Ltd. |
Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
|
FR2680512B1
(fr)
*
|
1991-08-20 |
1995-01-20 |
Adir |
Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
|
GB9124513D0
(en)
*
|
1991-11-19 |
1992-01-08 |
Smithkline Beecham Plc |
Novel process
|
US5741803A
(en)
*
|
1992-09-05 |
1998-04-21 |
Smithkline Beecham Plc |
Substituted thiazolidinedionle derivatives
|
GB9218830D0
(en)
*
|
1992-09-05 |
1992-10-21 |
Smithkline Beecham Plc |
Novel compounds
|
CZ181493A3
(en)
*
|
1992-09-10 |
1994-03-16 |
Lilly Co Eli |
The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease
|
US5594016A
(en)
*
|
1992-12-28 |
1997-01-14 |
Mitsubishi Chemical Corporation |
Naphthalene derivatives
|
JP2845743B2
(ja)
*
|
1992-12-28 |
1999-01-13 |
三菱化学株式会社 |
新規なナフタレン誘導体
|
USRE39384E1
(en)
|
1993-09-01 |
2006-11-07 |
Smithkline Beecham P.L.C. |
Substituted thiazolidinedione derivatives
|
US6046222A
(en)
*
|
1993-09-15 |
2000-04-04 |
Warner-Lambert Company |
Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
|
US5478852C1
(en)
*
|
1993-09-15 |
2001-03-13 |
Sankyo Co |
Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
|
CN1103590C
(zh)
*
|
1993-09-15 |
2003-03-26 |
三共株式会社 |
使用噻唑烷二酮防止或延缓非胰岛素依赖性糖尿病(niddm)的发作
|
US5874454A
(en)
*
|
1993-09-15 |
1999-02-23 |
Warner-Lambert Company |
Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
|
RU2126395C1
(ru)
*
|
1994-03-08 |
1999-02-20 |
Американ Хоум Продактс Корпорейшн |
Производные тиазолидиндиона или их фармацевтически приемлемые соли, способ лечения гипергликемии у млекопитающего, фармацевтическая композиция
|
US6251928B1
(en)
*
|
1994-03-16 |
2001-06-26 |
Eli Lilly And Company |
Treatment of alzheimer's disease employing inhibitors of cathepsin D
|
CA2201113A1
(en)
*
|
1994-10-20 |
1996-05-02 |
Yutaka Nomura |
Quinoline derivatives
|
US5708012A
(en)
*
|
1995-04-28 |
1998-01-13 |
Sankyo Company, Limited |
Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
|
WO1996035688A1
(fr)
*
|
1995-05-08 |
1996-11-14 |
Nippon Chemiphar Co., Ltd. |
Derives de 2,4-thiazolidinedione ou d'oxazolidinedione et agent hypoglycemique
|
TWI238064B
(en)
*
|
1995-06-20 |
2005-08-21 |
Takeda Chemical Industries Ltd |
A pharmaceutical composition for prophylaxis and treatment of diabetes
|
NO318765B1
(no)
*
|
1995-07-03 |
2005-05-02 |
Sankyo Co |
Anvendelse av en HMG-CoA reduktaseinhibitor og en insulinsensibilisator til fremstilling av et medikament for forebyggelse eller behandling av arteriosklerose eller xantom, samt pakket farmasoytisk preparat som omfatter de to midlene i separate porsjoner.
|
EP0783888A1
(en)
|
1995-12-26 |
1997-07-16 |
Sankyo Company Limited |
Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
|
NZ314406A
(en)
*
|
1996-03-18 |
2000-12-22 |
Sankyo Co |
Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
|
WO1997040017A2
(en)
*
|
1996-04-19 |
1997-10-30 |
Novo Nordisk A/S |
Modulators of molecules with phosphotyrosine recognition units
|
US5958957A
(en)
*
|
1996-04-19 |
1999-09-28 |
Novo Nordisk A/S |
Modulators of molecules with phosphotyrosine recognition units
|
CA2257284C
(en)
*
|
1996-05-31 |
2005-10-04 |
Sankyo Company Limited |
Remedy for autoimmune diseases
|
US5952509A
(en)
*
|
1996-06-27 |
1999-09-14 |
Takeda Chemical Industries, Ltd. |
Production of benzaldehyde compounds
|
US6121288A
(en)
*
|
1996-11-08 |
2000-09-19 |
Nippon Chemiphar Co., Ltd. |
Visceral fat lowering agent
|
EP1006794B1
(en)
*
|
1997-03-12 |
2007-11-28 |
Robert W. Esmond |
A method for treating or preventing alzheimer's disease
|
US5908859A
(en)
*
|
1997-08-11 |
1999-06-01 |
Eli Lilly And Company |
Benzothiophenes for inhibiting hyperlipidemia
|
HUP9902721A2
(hu)
|
1997-11-25 |
1999-12-28 |
The Procter & Gamble Co. |
Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
|
GB9726568D0
(en)
*
|
1997-12-16 |
1998-02-11 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
AU1507799A
(en)
*
|
1997-12-16 |
1999-07-05 |
Sankyo Company Limited |
Leukemia remedy
|
US20040058873A1
(en)
*
|
1998-03-12 |
2004-03-25 |
Esmond Robert W. |
Method for treating or preventing Alzheimer's disease
|
CA2350599A1
(en)
*
|
1998-11-20 |
2000-06-02 |
Genentech, Inc. |
Method of inhibiting angiogenesis
|
US6191154B1
(en)
|
1998-11-27 |
2001-02-20 |
Case Western Reserve University |
Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
|
TWI249401B
(en)
*
|
1999-04-14 |
2006-02-21 |
Takeda Chemical Industries Ltd |
Agent for improving ketosis
|
JP4693247B2
(ja)
|
1999-04-28 |
2011-06-01 |
有限会社ケムフィズ |
複素環カルボン酸誘導体
|
ID29875A
(id)
*
|
1999-07-01 |
2001-10-18 |
Geron Corp Cs |
Penghambat-penghambat telomerase dan metode penggunaannya
|
JP2001072592A
(ja)
|
1999-07-01 |
2001-03-21 |
Kyowa Hakko Kogyo Co Ltd |
テロメラーゼ阻害剤
|
US7390824B1
(en)
*
|
1999-09-07 |
2008-06-24 |
Bristol-Myers Squibb Company |
Method for treating diabetes employing an aP2 inhibitor and combination
|
US6559188B1
(en)
|
1999-09-17 |
2003-05-06 |
Novartis Ag |
Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
|
CO5200844A1
(es)
|
1999-09-17 |
2002-09-27 |
Novartis Ag |
Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
|
US6878749B2
(en)
|
1999-09-17 |
2005-04-12 |
Novartis Ag |
Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
|
ES2156574B1
(es)
*
|
1999-11-18 |
2002-02-01 |
Vita Invest Sa |
Nuevos derivados de tiazolidindiona como agentes antidiabeticos
|
MXPA02005528A
(es)
|
1999-12-03 |
2002-09-02 |
Kyoto Pharma Ind |
Compuestos heterociclicos sus sales y uso medicinal.
|
DK1741445T3
(da)
|
2000-01-21 |
2013-11-04 |
Novartis Ag |
Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
|
US6784199B2
(en)
*
|
2000-09-21 |
2004-08-31 |
Aryx Therapeutics |
Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis in mammals
|
US6958355B2
(en)
*
|
2000-04-24 |
2005-10-25 |
Aryx Therapeutics, Inc. |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
US6680387B2
(en)
*
|
2000-04-24 |
2004-01-20 |
Aryx Therapeutics |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
EA004244B1
(ru)
*
|
2000-04-25 |
2004-02-26 |
Киорин Фармасьютикал Ко., Лтд. |
Новый стабильный кристалл производного тиазолидиндиона и способ его получения
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
US6452014B1
(en)
|
2000-12-22 |
2002-09-17 |
Geron Corporation |
Telomerase inhibitors and methods of their use
|
EP1354602B1
(en)
*
|
2000-12-26 |
2006-10-04 |
Sankyo Company, Limited |
Medicinal compositions containing diuretic and insulin resistance-improving agent
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
ES2290562T3
(es)
*
|
2001-01-26 |
2008-02-16 |
Schering Corporation |
Combinaciones del activador del receptor activado por el proliferador de los peroxisomas (ppar) fenofibrato con el inhibidor de la absorcion de esteroles ezetimiba para indicaciones vasculares.
|
DE60221798T2
(de)
*
|
2001-01-26 |
2008-06-05 |
Schering Corp. |
Kombinationen von gallensäure sequestriermitteln und hemmern der sterol absorption zur behandlung von kardiovaskulären indikationen
|
PL205343B1
(pl)
*
|
2001-01-26 |
2010-04-30 |
Schering Corp |
Zastosowanie inhibitora wchłaniania sterolu
|
WO2002058734A2
(en)
*
|
2001-01-26 |
2002-08-01 |
Schering Corporation |
Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
|
US20020183305A1
(en)
*
|
2001-01-26 |
2002-12-05 |
Schering Corporation |
Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
|
CZ20032031A3
(cs)
*
|
2001-01-26 |
2003-12-17 |
Schering Corporation |
Farmaceutický prostředek
|
EP1953162B9
(de)
*
|
2001-02-24 |
2012-10-31 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
KR200249057Y1
(ko)
*
|
2001-03-22 |
2001-10-19 |
김진환 |
뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
|
ATE423559T1
(de)
*
|
2001-04-04 |
2009-03-15 |
Ortho Mcneil Janssen Pharm |
Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren
|
US20060047000A1
(en)
*
|
2001-04-24 |
2006-03-02 |
Aryx Therapeutics, Inc. |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
CA2445322C
(en)
*
|
2001-04-25 |
2011-06-14 |
Takeda Chemical Industries, Ltd. |
Use of the abc expression promoting agent pioglitazone for the treatment of arteriosclerosis obliterans
|
US7009057B2
(en)
|
2001-04-26 |
2006-03-07 |
Zentiva A.S. |
Method for obtaining pioglitazone as an antidiabetic agent
|
JP4279137B2
(ja)
*
|
2001-05-29 |
2009-06-17 |
京都薬品工業株式会社 |
新規複素環誘導体およびその医薬用途
|
CN1242994C
(zh)
*
|
2001-05-29 |
2006-02-22 |
京都药品工业株式会社 |
杂环化合物及其医疗用途
|
EP1413315A4
(en)
*
|
2001-08-03 |
2006-08-16 |
Takeda Pharmaceutical |
DRUGS WITH CONTINUOUS RELEASE
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
EP1429756B1
(en)
*
|
2001-09-21 |
2006-11-22 |
Schering Corporation |
Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
EP1427409B1
(en)
*
|
2001-09-21 |
2008-10-15 |
Schering Corporation |
Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
|
US7056906B2
(en)
*
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
US7135485B2
(en)
*
|
2001-09-28 |
2006-11-14 |
Teva Pharmaceutical Industries Ltd. |
Pioglitazone hydrochloride
|
US20050101638A1
(en)
*
|
2002-11-08 |
2005-05-12 |
Webb Randy L. |
Combination of organic compounds
|
US20050187258A1
(en)
*
|
2001-12-20 |
2005-08-25 |
Ben-Zion Dolitzky |
Hydrogenation of precursors to thiazolidinedione antihyperglycemics
|
EP1465881A4
(en)
*
|
2001-12-20 |
2005-04-13 |
Teva Pharma |
HYDROGENATION OF PRECURSORS OF ANTI-HYPERGLYCEMIATING THIAZOLIDINEDIONE SUBSTANCES
|
ITRM20020016A1
(it)
*
|
2002-01-15 |
2003-07-15 |
Sigma Tau Ind Farmaceuti |
Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
|
CA2474353A1
(en)
*
|
2002-01-23 |
2003-07-31 |
Yamanouchi Pharmaceutical Co., Ltd. |
Method for screening a drug ameliorating insulin resistance
|
US7015345B2
(en)
*
|
2002-02-21 |
2006-03-21 |
Asahi Kasei Pharma Corporation |
Propionic acid derivatives
|
KR100450700B1
(ko)
*
|
2002-03-22 |
2004-10-01 |
주식회사종근당 |
티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물
|
US20050119314A1
(en)
*
|
2002-04-05 |
2005-06-02 |
Sankyo Company, Limited |
Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
|
KR100897890B1
(ko)
|
2002-06-17 |
2009-05-18 |
인벤티아 헬스케어 피브이티. 엘티디. |
티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법
|
US8993773B2
(en)
|
2002-07-16 |
2015-03-31 |
Cadila Healthcare Limited |
Process to prepare pioglitazone via several novel intermediates
|
ATE372336T1
(de)
|
2002-07-16 |
2007-09-15 |
Cadila Healthcare Ltd |
Prozess zur herstellung von pioglitazon via verschiedene zwischenstufen
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
WO2004024059A2
(en)
*
|
2002-09-12 |
2004-03-25 |
Themis Laboratories Private Limited, |
Improved process for preparation of thiazolidinedione derivatives
|
US9060941B2
(en)
*
|
2002-09-20 |
2015-06-23 |
Actavis, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US8084058B2
(en)
|
2002-09-20 |
2011-12-27 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US7959946B2
(en)
*
|
2002-09-20 |
2011-06-14 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US7785627B2
(en)
|
2002-09-20 |
2010-08-31 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
ES2529180T3
(es)
|
2002-09-20 |
2015-02-17 |
Andrx Labs Llc |
Formulación multietapa que contiene una biguanida y un derivado de tiazolidinodiona
|
WO2004043456A1
(en)
*
|
2002-11-06 |
2004-05-27 |
Schering Corporation |
Cholesterol absorption inhibitors for the treatment of demyelination
|
US7208486B2
(en)
|
2003-03-07 |
2007-04-24 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
WO2004081002A1
(en)
|
2003-03-07 |
2004-09-23 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
CA2517573C
(en)
|
2003-03-07 |
2011-12-06 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
US20040242568A1
(en)
|
2003-03-25 |
2004-12-02 |
Syrrx, Inc. |
Dipeptidyl peptidase inhibitors
|
WO2004108721A1
(en)
*
|
2003-04-01 |
2004-12-16 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl] methyl]-2,4-thiazolidinedione
|
ES2219180B1
(es)
*
|
2003-05-09 |
2006-03-01 |
Medichem, S.A. |
Compuesto intermedio util para la preparacion de pioglitazona.
|
EP1640374A1
(en)
*
|
2003-05-13 |
2006-03-29 |
Synthon B.V. |
Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
|
EP1622898A1
(en)
*
|
2003-05-13 |
2006-02-08 |
Synthon B.V. |
Processes for making thiazolidinedione derivatives and compounds thereof
|
US7230016B2
(en)
*
|
2003-05-13 |
2007-06-12 |
Synthon Ip Inc. |
Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
|
US20050004179A1
(en)
*
|
2003-05-22 |
2005-01-06 |
Pedersen Ward A. |
Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
|
JPWO2004106542A1
(ja)
*
|
2003-05-29 |
2006-07-20 |
三共株式会社 |
インスリン抵抗性改善剤及びそのスクリーニング方法
|
WO2004106299A2
(en)
|
2003-05-30 |
2004-12-09 |
Ranbaxy Laboratories Limited |
Substituted pyrrole derivatives and their use as hmg-co inhibitors
|
US7790736B2
(en)
|
2003-08-13 |
2010-09-07 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
WO2005021542A2
(en)
*
|
2003-08-28 |
2005-03-10 |
Ranbaxy Laboratories Limited |
Process for the preparation of pioglitazone
|
WO2005021543A1
(en)
*
|
2003-09-03 |
2005-03-10 |
Biocon Limited |
Phosphoric acid salt of 5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2, 4-thiazolidinedione
|
US7790734B2
(en)
|
2003-09-08 |
2010-09-07 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
JP5140881B2
(ja)
*
|
2003-09-17 |
2013-02-13 |
要 川杉 |
医薬組成物
|
WO2005046797A2
(en)
*
|
2003-11-05 |
2005-05-26 |
Schering Corporation |
Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
|
US7501426B2
(en)
*
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
WO2005080387A2
(en)
*
|
2004-02-20 |
2005-09-01 |
Synthon B.V. |
Processes for making pioglitazone and compounds of the processes
|
CN102134229B
(zh)
|
2004-03-15 |
2020-08-04 |
武田药品工业株式会社 |
二肽基肽酶抑制剂
|
KR20070011329A
(ko)
*
|
2004-03-29 |
2007-01-24 |
상꾜 가부시키가이샤 |
인슐린 저항성 개선제를 함유하는 당뇨병 치료제
|
US7161756B2
(en)
*
|
2004-05-10 |
2007-01-09 |
Tandberg Data Storage Asa |
Method and system for communication between a tape drive and an external device
|
US20060025478A1
(en)
*
|
2004-07-27 |
2006-02-02 |
Keisuke Inoue |
Medicine for prevention or treatment of diabetes
|
TW200608967A
(en)
*
|
2004-07-29 |
2006-03-16 |
Sankyo Co |
Pharmaceutical compositions containing with diabetic agent
|
JP4854511B2
(ja)
*
|
2004-08-26 |
2012-01-18 |
武田薬品工業株式会社 |
糖尿病治療剤
|
WO2006035459A1
(en)
*
|
2004-09-28 |
2006-04-06 |
Morepen Laboratories Limited |
An improved process for the production of derivatives of thiozolidinediones and their precursors
|
US20060089387A1
(en)
*
|
2004-10-26 |
2006-04-27 |
Le Huang |
Stabilized pharmaceutical composition comprising antidiabetic agent
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
US7833513B2
(en)
|
2004-12-03 |
2010-11-16 |
Rhode Island Hospital |
Treatment of Alzheimer's Disease
|
WO2006068978A2
(en)
|
2004-12-21 |
2006-06-29 |
Takeda Pharmaceutial Company Limited |
Dipeptidyl peptidase inhibitors
|
EA015382B1
(ru)
*
|
2005-03-08 |
2011-08-30 |
Никомед Гмбх |
Применение рофлумиласта для лечения сахарного диабета типа 2
|
US20070269486A1
(en)
*
|
2005-03-14 |
2007-11-22 |
Conor Medsystems, Llc. |
Methods and Devices for Reducing Tissue Damage After Ischemic Injury
|
KR20080025662A
(ko)
*
|
2005-03-18 |
2008-03-21 |
오키드 케미칼즈 앤드 파마수티컬즈 리미티드 |
신규 티로신 유도체
|
WO2006117654A1
(en)
*
|
2005-05-03 |
2006-11-09 |
Ranbaxy Laboratories Limited |
Processes for the preparation of pioglitazone or salts thereof
|
CA2615118A1
(en)
*
|
2005-07-12 |
2007-01-18 |
Daiichi Sankyo Company, Limited |
Pharmaceutical composition containing ppar.gamma. agonist
|
US20090203744A1
(en)
*
|
2005-07-29 |
2009-08-13 |
Pande Y Surendrakumar Satyanarayan |
Novel pyridine derivatives
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
PL1942898T5
(pl)
*
|
2005-09-14 |
2014-10-31 |
Takeda Pharmaceuticals Co |
Inhibitory peptydazy dipeptydylowej do leczenia cukrzycy
|
CN102675221A
(zh)
|
2005-09-16 |
2012-09-19 |
武田药品工业株式会社 |
用于制备嘧啶二酮衍生物的方法中的中间体
|
TW200738266A
(en)
*
|
2005-09-29 |
2007-10-16 |
Sankyo Co |
Pharmaceutical agent containing insulin resistance improving agent
|
KR101329112B1
(ko)
|
2005-11-08 |
2013-11-14 |
랜박시 래보러터리스 리미티드 |
(3r,5r)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
|
TW200730173A
(en)
*
|
2005-12-16 |
2007-08-16 |
Sankyo Co |
Pharmaceutical composition enhancing production of adiponectin
|
MX356584B
(es)
|
2006-03-16 |
2018-06-05 |
Metabolic Solutions Dev Co |
Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica.
|
NZ571872A
(en)
*
|
2006-03-16 |
2011-05-27 |
Metabolic Solutions Dev Co |
Combination therapies of thiazolidinedione analogues and glucocorticoid agonists
|
CA2646149A1
(en)
*
|
2006-03-16 |
2007-09-27 |
Metabolic Solutions Development Company |
Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
EA030606B1
(ru)
|
2006-05-04 |
2018-08-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Способы приготовления лекарственного средства, содержащего полиморфы
|
EP2452683A3
(en)
|
2006-06-26 |
2012-08-22 |
Amgen Inc. |
Methods for treating atherosclerosis
|
KR100791399B1
(ko)
|
2006-09-06 |
2008-01-07 |
동우신테크 주식회사 |
염산 피오글리타존의 제조방법
|
BRPI0716134A2
(pt)
|
2006-09-07 |
2013-09-17 |
Nycomed Gmbh |
tratamento de combinaÇço para diabetes mellitus
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
US20080182880A1
(en)
*
|
2006-09-28 |
2008-07-31 |
Mailatur Sivaraman Mohan |
Pioglitazone composition
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
JP2010513276A
(ja)
*
|
2006-12-13 |
2010-04-30 |
ギリード・サイエンシズ・インコーポレーテッド |
肺炎症および気管支収縮の治療のための抗炎症シグナル伝達モジュレーター(AISTM)およびβ−アゴニストの相互プロドラッグとしてのモノホスフェート
|
WO2008075380A2
(en)
*
|
2006-12-21 |
2008-06-26 |
Ind-Swift Laboratories Limited |
Process for the preparation of thiazolidine derivatives
|
US20080176905A1
(en)
*
|
2007-01-22 |
2008-07-24 |
Santiago Ini |
Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof
|
UA95828C2
(ru)
*
|
2007-02-01 |
2011-09-12 |
Такеда Фармасьютикал Компани Лимитед |
Твердая рецептура, которая содержит алоглиптин и пиоглитазон
|
EP1988091B1
(en)
|
2007-02-07 |
2015-06-10 |
Kyowa Hakko Kirin Co., Ltd. |
Tricyclic compounds
|
WO2008105326A1
(ja)
*
|
2007-02-28 |
2008-09-04 |
Ohara Chemical Industries, Ltd. |
2-イミノ-4-チアゾリジノン誘導体及び2,4-チアゾリジンジオン誘導体の製造方法
|
CL2008000684A1
(es)
|
2007-03-09 |
2008-08-01 |
Indigene Pharmaceuticals Inc |
Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
|
US8093236B2
(en)
*
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
KR20140012199A
(ko)
|
2007-03-30 |
2014-01-29 |
암브룩스, 인코포레이티드 |
변형된 fgf-21 폴리펩티드 및 그 용도
|
WO2008124122A1
(en)
*
|
2007-04-09 |
2008-10-16 |
Scidose, Llc |
Combinations of statins and anti-obesity agent and glitazones
|
US11241420B2
(en)
|
2007-04-11 |
2022-02-08 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|
ES2830073T3
(es)
|
2007-04-11 |
2021-06-02 |
Omeros Corp |
Composiciones y métodos para la profilaxis y el tratamiento de adicciones
|
US20160331729A9
(en)
*
|
2007-04-11 |
2016-11-17 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
ES2393885T7
(es)
|
2007-06-04 |
2014-01-30 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
KR101560844B1
(ko)
|
2007-06-04 |
2015-10-15 |
벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 |
트라이-아릴계 화합물 및 이를 포함하는 조성물
|
EA201070187A1
(ru)
|
2007-07-26 |
2010-08-30 |
Эмджен Инк. |
Модифицированные ферменты лецитин-холестерин ацилтрансферазы
|
EP3542801A1
(en)
*
|
2007-08-17 |
2019-09-25 |
Boehringer Ingelheim International GmbH |
Purin derivatives for use in the treatment of fap-related diseases
|
US7960376B2
(en)
*
|
2007-09-14 |
2011-06-14 |
Cara Therapeutics, Inc. |
Benzo-fused heterocycles
|
EP2203433B1
(en)
|
2007-09-14 |
2012-10-31 |
Metabolic Solutions Development Company LLC |
5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione for use in treating diabetes
|
US8304441B2
(en)
|
2007-09-14 |
2012-11-06 |
Metabolic Solutions Development Company, Llc |
Thiazolidinedione analogues for the treatment of metabolic diseases
|
US8722710B2
(en)
|
2007-09-26 |
2014-05-13 |
Deuterx, Llc |
Deuterium-enriched pioglitazone
|
US20090118514A1
(en)
*
|
2007-11-06 |
2009-05-07 |
Raghupathi Reddy Anumula |
Processes for preparing pioglitazone and its pharmaceutically acceptable salts
|
JP5334422B2
(ja)
*
|
2008-02-13 |
2013-11-06 |
株式会社トクヤマ |
5−{4−[2−(5−エチル−2−ピリジル)エトキシ]ベンジル}−2−イミノ−4−チアゾリジノンの製造方法
|
JP5197063B2
(ja)
*
|
2008-02-21 |
2013-05-15 |
株式会社トクヤマ |
2−ブロモ−3−{4−[2−(5−エチル−2−ピリジル)エトキシ]フェニル}プロピオン酸メチルの製造方法
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
JP2011518877A
(ja)
*
|
2008-04-28 |
2011-06-30 |
エレジーレ ソシエタ ペル アチオニ |
4−[2−(5−エチル−2−ピリジル)エトキシ]ニトロベンゼン及びピオグリタゾンの調製方法
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
ES2522968T3
(es)
|
2008-06-04 |
2014-11-19 |
Synergy Pharmaceuticals Inc. |
Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
AU2009270833B2
(en)
|
2008-07-16 |
2015-02-19 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
KR20200118243A
(ko)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
WO2010016549A1
(ja)
|
2008-08-06 |
2010-02-11 |
協和発酵キリン株式会社 |
3環系化合物
|
US8846315B2
(en)
|
2008-08-12 |
2014-09-30 |
Zinfandel Pharmaceuticals, Inc. |
Disease risk factors and methods of use
|
US8815508B2
(en)
*
|
2008-08-12 |
2014-08-26 |
Zinfandel Pharmaceuticals, Inc. |
Method of identifying disease risk factors
|
PE20110297A1
(es)
*
|
2008-08-15 |
2011-05-26 |
Boehringer Ingelheim Int |
Inhibidores de dpp-4 para la cicatrizacion de heridas
|
JP5553759B2
(ja)
*
|
2008-09-02 |
2014-07-16 |
株式会社トクヤマ |
脱臭化水素化抑制剤
|
KR20110067096A
(ko)
|
2008-09-10 |
2011-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
당뇨병 및 관련 상태를 치료하기 위한 병용 요법
|
KR20110068979A
(ko)
*
|
2008-10-10 |
2011-06-22 |
가부시끼가이샤 도꾸야마 |
카르보닐옥시 화합물의 제조 방법
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
JP5473303B2
(ja)
*
|
2008-12-01 |
2014-04-16 |
株式会社トクヤマ |
2−ブロモ−3−{4−[2−(5−エチル−2−ピリジル)エトキシ]フェニル}プロピオン酸メチルの製造方法
|
US20100144140A1
(en)
*
|
2008-12-10 |
2010-06-10 |
Novellus Systems, Inc. |
Methods for depositing tungsten films having low resistivity for gapfill applications
|
JP2012512848A
(ja)
|
2008-12-23 |
2012-06-07 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
有機化合物の塩の形態
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
JP5511690B2
(ja)
*
|
2009-01-20 |
2014-06-04 |
株式会社トクヤマ |
2−ブロモ−3−{4−[2−(5−エチル−2−ピリジル)エトキシ]フェニル}プロピオン酸メチルの脱臭化水素化を抑制する方法
|
JP2010208957A
(ja)
*
|
2009-03-06 |
2010-09-24 |
Tokuyama Corp |
結晶構造を有する5−{4−[2−(5−エチル−2−ピリジル)エトキシ]ベンジル}−2−イミノ−4−チアゾリジノン及びその製造方法
|
WO2010105103A1
(en)
|
2009-03-11 |
2010-09-16 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|
EP3309151A1
(en)
|
2009-06-25 |
2018-04-18 |
Alkermes Pharma Ireland Limited |
Heterocyclic compounds for the treatment of neurological and psychological disorders
|
CA2766033C
(en)
|
2009-06-25 |
2016-09-20 |
Alkermes, Inc. |
Prodrugs of nh-acidic compounds
|
US20110065756A1
(en)
*
|
2009-09-17 |
2011-03-17 |
De Taeye Bart M |
Methods and compositions for treatment of obesity-related diseases
|
WO2011059053A1
(ja)
|
2009-11-13 |
2011-05-19 |
東レ株式会社 |
糖尿病の治療または予防薬
|
BR112012012641A2
(pt)
|
2009-11-27 |
2020-08-11 |
Boehringer Ingelheim International Gmbh |
TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
|
ES2658168T3
(es)
*
|
2009-12-15 |
2018-03-08 |
Cirius Therapeutics, Inc. |
Sales de tiazolidinadiona ahorradoras de PPAR para el tratamiento de enfermedades metabólicas
|
AU2011207210A1
(en)
|
2010-01-22 |
2012-08-16 |
Dana-Farber Cancer Institute, Inc. |
Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
|
WO2011120923A1
(en)
|
2010-03-30 |
2011-10-06 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
|
WO2011138421A1
(en)
|
2010-05-05 |
2011-11-10 |
Boehringer Ingelheim International Gmbh |
Combination therapy
|
EP3366304B1
(en)
|
2010-06-24 |
2020-05-13 |
Boehringer Ingelheim International GmbH |
Diabetes therapy
|
EP2611434A1
(en)
|
2010-09-01 |
2013-07-10 |
Lupin Limited |
Pharmaceutical composition comprising metformin and pioglitazone
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
EA201691399A1
(ru)
|
2011-01-10 |
2016-10-31 |
Зинфандел Фармасьютикалз, Инк. |
Способы и готовые лекарственные формы для лечения болезни альцгеймера
|
WO2012153312A1
(en)
|
2011-05-11 |
2012-11-15 |
Ranbaxy Laboratories Limited |
Process for the purification of pioglitazone
|
WO2013010964A1
(en)
|
2011-07-15 |
2013-01-24 |
Boehringer Ingelheim International Gmbh |
Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
|
WO2013018899A1
(ja)
|
2011-08-03 |
2013-02-07 |
協和発酵キリン株式会社 |
ジベンゾオキセピン誘導体
|
WO2013068486A1
(en)
|
2011-11-08 |
2013-05-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of male infertility
|
CN104220460A
(zh)
|
2011-12-08 |
2014-12-17 |
安姆根有限公司 |
激动人lcat抗原结合蛋白和它们在疗法中的用途
|
CA2858787C
(en)
|
2011-12-15 |
2017-11-21 |
Alkermes Pharma Ireland Limited |
Prodrugs of tertiary amine compounds
|
US9504679B2
(en)
|
2011-12-19 |
2016-11-29 |
Bjoern Colin Kahrs |
Pharmaceutical compositions comprising glitazones and Nrf2 activators
|
US20130158077A1
(en)
|
2011-12-19 |
2013-06-20 |
Ares Trading S.A. |
Pharmaceutical compositions
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
EP2638898A1
(en)
|
2012-03-16 |
2013-09-18 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Metformin and Pioglitazone Formulation with Different Release Profiles
|
WO2013171167A1
(en)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
ES2668310T3
(es)
|
2012-11-05 |
2018-05-17 |
Commissariat à l'énergie atomique et aux énergies alternatives |
Combinación de un agente anticanceroso tal como un inhibidor de la tirosina cinasa y un antagonista STAT5, preferiblemente una tiazolidindiona, para eliminar las células madre de cáncer hematológico in vivo y para prevenir la recidiva de cáncer hematológico
|
US8969581B2
(en)
|
2013-03-14 |
2015-03-03 |
Deuterx, Llc |
5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
|
JP2016514671A
(ja)
|
2013-03-15 |
2016-05-23 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼのアゴニストおよびその使用
|
US20140275138A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Cba Pharma, Inc. |
Method and products for treating diabetes
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
US10011637B2
(en)
|
2013-06-05 |
2018-07-03 |
Synergy Pharmaceuticals, Inc. |
Ultra-pure agonists of guanylate cyclase C, method of making and using same
|
US9815777B2
(en)
|
2013-09-22 |
2017-11-14 |
Jiva Pharma, Inc. |
Metformin salts to treat Type2 diabetes
|
EP3065757A4
(en)
|
2013-10-09 |
2017-08-23 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
|
EA201690938A1
(ru)
|
2013-11-05 |
2016-11-30 |
Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити |
Соединения для лечения диабета и осложнений, возникающих из-за этого заболевания
|
US10188639B2
(en)
|
2014-01-15 |
2019-01-29 |
Deuterx, Llc |
Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
|
ES2950384T3
(es)
|
2014-02-28 |
2023-10-09 |
Boehringer Ingelheim Int |
Uso médico de un inhibidor de DPP-4
|
KR101606547B1
(ko)
*
|
2014-06-02 |
2016-03-28 |
김동연 |
공항 탑승객 위치조회시스템
|
KR20240024362A
(ko)
|
2014-10-24 |
2024-02-23 |
브리스톨-마이어스 스큅 컴퍼니 |
변형된 fgf-21 폴리펩티드 및 그의 용도
|
WO2016071727A1
(en)
|
2014-11-04 |
2016-05-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
|
MA39929A
(fr)
|
2014-11-27 |
2016-06-01 |
Arven Ilac Sanayi Ve Ticaret As |
Comprimé multicouche comprenant de la metformine et du pioglitazone
|
HUE053648T2
(hu)
|
2016-06-08 |
2021-07-28 |
Support Venture Gmbh |
Gyógyászati kombinációk rák kezelésére
|
EP3468562A1
(en)
|
2016-06-10 |
2019-04-17 |
Boehringer Ingelheim International GmbH |
Combinations of linagliptin and metformin
|
EP3500258A1
(en)
|
2016-08-17 |
2019-06-26 |
Support-Venture GmbH |
Method of preventing or treating hearing loss
|
TR201620309A2
(tr)
|
2016-12-30 |
2018-07-23 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Metformi̇n hi̇droklori̇t ve pi̇ogli̇tazon hi̇droklori̇ti̇n farmasöti̇k bi̇leşi̇mleri̇
|
SG10202110804WA
(en)
|
2017-04-04 |
2021-11-29 |
Kinarus Ag |
Methods of preventing or treating ophthalmic diseases
|
WO2019154893A1
(en)
|
2018-02-08 |
2019-08-15 |
Strekin Ag |
Oral extended release pharmaceutical compositions for preventing or treating hearing loss
|
WO2019154895A1
(en)
|
2018-02-08 |
2019-08-15 |
Strekin Ag |
Gel formulation for preventing or treating hearing loss
|
CA3092335A1
(en)
|
2018-03-05 |
2019-09-12 |
Alkermes Pharma Ireland Limited |
Aripiprazole dosing strategy
|
MA53114A
(fr)
|
2018-07-13 |
2021-05-19 |
Kinarus Ag |
Combinaisons d'agonistes de ppar et d'inhibiteurs de kinase p38 pour prévenir ou traiter des maladies fibrotiques
|
CN111875598B
(zh)
*
|
2020-05-23 |
2023-10-10 |
白银京宇新药业有限公司 |
一种吡格亚胺的制备方法
|
US11767317B1
(en)
|
2020-06-30 |
2023-09-26 |
Poxel Sa |
Methods of synthesizing enantiopure deuterium-enriched pioglitazone
|
US11319313B2
(en)
|
2020-06-30 |
2022-05-03 |
Poxel Sa |
Crystalline forms of deuterium-enriched pioglitazone
|
US20230263803A1
(en)
|
2020-08-11 |
2023-08-24 |
Kinarus Ag |
Methods of preventing or treating covid-19 and related viral diseases or disorders
|
CN116239601B
(zh)
|
2020-09-30 |
2023-10-13 |
映恩生物制药(苏州)有限公司 |
一种抗肿瘤化合物及其制备方法和应用
|
EP4385501A1
(en)
|
2022-12-15 |
2024-06-19 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A pharmaceutical formulation comprising linagliptin, pioglitazone and a sglt-2 inhibitor
|
EP4385502A1
(en)
|
2022-12-15 |
2024-06-19 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A pharmaceutical formulation comprising metformin, pioglitazone and a sglt-2 inhibitor
|